ArticleClinical, cosmetic and investigational dermatology2025
Global Burden of Non-Melanoma Skin Cancer Among Elder Adults and Projections to 2071: A Systematic and Comprehensive Analysis of the Global Burden of Disease Study 2021.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms and therapeutic design of stimuli-responsive vesicular nanocarriers for melanoma.International journal of pharmaceutics: X · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-melanoma skin cancer (NMSC) poses a significant health burden to the elderly globally. This study seeks to comprehensively assess the burden of NMSC among elderly adults in various regions and countries worldwide, covering the time frame from 1990 to 2021. Methods: Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed global trends in NMSC incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021. Joinpoint regression was used to evaluate temporal trends, and an Age-Period-Cohort (APC) model was applied to assess underlying influences. Future projections were made using the Bayesian Age-Period-Cohort (BAPC) model. Results: Data indicates that among all assessment metrics, both the number of cases and age-standardized rates are higher in males than in females, suggesting a more pronounced increase in the disease burden of NMSC among men. Concurrently, the disease burden is significantly higher in the elderly population compared to younger age groups. Across the 21 GBD regions worldwide, the disease burden is heaviest in high-income North America, particularly evident in age-standardized incidence rates (ASIR): from 395.30 (336.70-456.10)/100,000 (95% UI) in 1990, it rose to 1251.80 (1158.40-1341.20)/100,000 (95% UI) in 2015. Additionally, the disease burden and mortality rates in Australasia and Western Europe were generally higher than in other regions. East Asia exhibited a high annual estimated percentage change (EAPC) in age-standardized incidence of 7.1 (6.2-7.9) (95% CI), indicating that NMSC in this region is undergoing a rapid rise, thereby increasing the urgency for prevention and control. Conclusion: From 1990 to 2021, the global burden of NMSC has increased significantly. Elderly populations in various countries with high Standardized Disease Index values are facing a substantial disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.